Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : LastShadow's Position Trading -- Ignore unavailable to you. Want to Upgrade?

To: Jay Lyons who wrote (6429)	1/14/1999 8:33:00 PM
From: AlienTech	Respond to of 43080

Possis Medical Begins Trial On AngioJet Stroke Treatment Pdt MINNEAPOLIS (Dow Jones)--Possis Medical Inc. (POSS) began treating patients with its AngioJet Rheolytic Thrombectomy System for carotid stroke in its ReACT clinical trial. In a press release Thursday, Possis said the ReACT trial, approved by the Food and Drug Administration in 1988, calls for the treatment of 10 patients for acute stroke at up to five hospitals. The medical device company plans to enroll patients during the second half of the yearin a broader clinical trial investigating the use of AngioJet in more common strokes, it said. AngioJet removes clots in the brain to restore blood flow. (END) DOW JONES NEWS 01-14-99 11:19 AM